## Amendments to the claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

## **Listing of Claims:**

1.(currently amended)

A compound having the formula

$$(R^1)_m$$
 $R^2$ 
 $(CH_2)_n$ 
 $(I)$ 

wherein:

R<sup>1</sup> is H, NO<sub>2</sub>, halo, NR<sup>6</sup>R<sup>7</sup>, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub>haloalkyl, R<sup>6</sup>CO, R<sup>6</sup>OCO or CONR<sup>6</sup>R<sup>7</sup>;

m is 0, 1, 2 or 3;

 $R^2$  is NO<sub>2</sub>, halo, NR<sup>6</sup>R<sup>7</sup>, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub>haloalkylO, cyano, R<sup>6</sup>OC<sub>0-6</sub>alkyl, R<sup>6</sup>CO, R<sup>6</sup>OCO, R<sup>6</sup>CONR<sup>7</sup>, R<sup>6</sup>R<sup>7</sup>NCO, R<sup>8</sup>SO<sub>2</sub>, R<sup>8</sup>SO<sub>2</sub>HN, arylC<sub>0-6</sub>alkyl or heteroarylC<sub>0-6</sub>alkyl;

 $R^3$  and  $R^9$  are each independently H or  $C_{1\text{--}4}$ alkyl;

p is 0, 1 or 2;

n is 0, 2, 3 or 4;

 $R^5$  is  $C_{1-10}$ alkyl,  $C_{6-10}$ aryl $C_{0-6}$ alkyl,  $C_{3-7}$ cycloalkyl $C_{0-6}$ alkyl or  $C_{5-6}$ heteroaryl $C_{0-6}$ alkyl, whereby any aryl, heteroaryl or cycloalkyl may be fused with aryl, heteroaryl,

 $C_{3-7}$ cycloalkyl or  $C_{3-7}$ heterocycloalkyl, and which  $R^5$  may be substituted with one or more A;

A is H, OH, NO<sub>2</sub>, cyano, R<sup>6</sup>CO, R<sup>6</sup>O(CO), halo, C<sub>1-6</sub>alkyl, NR<sup>6</sup>R<sup>7</sup>, C<sub>1-6</sub>haloalkyl,

 $C_{1\text{-}6} haloalkylO,\, R^6 O C_{0\text{-}6} alkyl,\, hydroxy C_{1\text{-}6} alkyl,\, R^8 S O_2,\, R^8 S O_2 HN,\, C_{5\text{-}6} arylO\,\, or\, CONR^6 R^7;$ 

R<sup>6</sup> and R<sup>7</sup> are each independently H or C<sub>1-6</sub>alkyl; and

R<sup>8</sup> is NR<sup>6</sup>R<sup>7</sup> or C<sub>1-4</sub>alkyl,

or a <u>pharmaceutically acceptable salt thereof</u>, <u>solvate or solvated salt thereof</u>, <u>with the proviso</u> that the compound is not methyl-4-[[(7-methyl-1H-benzimidazol-1-yl)acetyl]amino]benzoate.

2.(currently amended) A compound according to claim 1, wherein:

 $R^1$  is H, halo,  $NR^6R^7$ ,  $C_{1\text{-}6}$ alkyl,  $C_{1\text{-}6}$ haloalkyl,  $C_{1\text{-}6}$ haloalkylO,  $R^6OC_{0\text{-}6}$ alkyl,  $R^6CO$ ,  $R^6OCO$  or  $CONR^6R^7$ ;

m is 0 or 1;

 $R^2$  is  $NO_2$ , halo,  $NR^6R^7$ ,  $C_{1-6}$ alkyl,  $C_{1-6}$ haloalkyl, cyano,  $R^6OCO$ ,  $R^6CONR^7$ ,  $R^8SO_2$ ,  $R^8SO_2HN$  or heteroaryl $C_{0-6}$ alkyl;

R<sup>3</sup> and R<sup>9</sup> are each independently H or C<sub>1-4</sub>alkyl;

p is 0;

n is 0;

 $R^5$  is  $C_{1-10}$ alkyl,  $C_{6-10}$ aryl $C_{0-6}$ alkyl or  $C_{5-6}$ heteroaryl $C_{0-6}$ alkyl, whereby any aryl may be fused with  $C_{3-7}$ cycloalkyl or  $C_{3-7}$ heterocycloalkyl, and which  $R^5$  may be substituted with one or more A;

A is H, cyano, halo,  $NO_2$ ,  $C_{1-6}$ alkyl,  $NR^6R^7$ ,  $C_{1-6}$ haloalkyl,  $C_{1-6}$ haloalkylO,  $R^6OC_{0-6}$ 6alkyl, hydroxy $C_{1-6}$ alkyl,  $R^8SO_2$  or  $C_{5-6}$ arylO;

R<sup>6</sup> and R<sup>7</sup> are each independently H or C<sub>1-6</sub>alkyl; and

R<sup>8</sup> is NR<sup>6</sup>R<sup>7</sup> or C<sub>1-4</sub>alkyl,

or a <u>pharmaceutically acceptable salt thereof</u>, <u>solvate or solvated salt thereof</u>, <u>with the proviso</u> that the compound is not methyl-4-[[(7-methyl-1H-benzimidazol-1-yl)acetyl]amino]benzoate.

3.(currently amended) A compound according to claim 1, wherein

 $R^2$  is  $NO_2$ , halo,  $NR^6R^7$ ,  $C_{1\text{-4}}$ alkyl,  $C_{1\text{-4}}$ haloalkyl,  $C_{1\text{-2}}$ haloalkylO, cyano,  $R^6OC_{0\text{-4}}$ alkyl,  $R^6CO$ ,  $R^6OCO$ ,  $R^6CONR^7$ ,  $R^6R^7NCO$ ,  $R^8SO_2$ ,  $R^8SO_2HN$ , aryl $C_{0\text{-6}}$ alkyl and heteroaryl and wherein

 $R^6$  and  $R^7$  are each independently H or  $C_{1\text{--}4}$ alkyl and

R<sup>8</sup> is NR<sup>6</sup>R<sup>7</sup> or C<sub>1-3</sub>alkyl,

or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof, with the proviso that the compound is not methyl-4-[[(7-methyl-1H-benzimidazol-1-yl)acetyl]amino]benzoate.

4.(currently amended) A compound according to claim 1, wherein  $R^2$  is  $NO_2$ ,

PCT Application Number PCT/SE2004/000738 Amendment dated 10/16/2008 AstraZeneca Docket Number 101062-1P US

or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof, with the proviso that the compound is not methyl-4-[[(7-methyl-1H-benzimidazol-1-yl)acetyl]amino]benzoate.

5.(currently amended) A compound according to claim 1, wherein R<sup>5</sup> is phenyl, which may be substituted with one or more A, or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof, with the proviso that the compound is not methyl-4-[[(7-methyl-1H-benzimidazol-1-yl)acetyl]amino]benzoate.

6.(currently amended) A compound according to claim 5, wherein A is selected from the group consisting of halo, alkoxy, haloalkoxy, haloalkyl, alkyl, alkanol, cyano, phenoxy, alkylsulfonyl and (di)alkylamino,

or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof, with the proviso that the compound is not methyl-4-[[(7-methyl-1H-benzimidazol-1-yl)acetyl]amino]benzoate.

7.(currently amended) A compound according to claim 1, wherein A is selected from the group consisting of fluoro, iodo, chloro, bromo, methoxy, ethoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, tetrafluoroethoxy, methyl, ethyl, propyl, butyl, hydroxyethyl, cyano, phenoxymethylsulfonyl and dimethylamino, or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof, with the proviso that the compound is not methyl-4-[[(7-methyl-1H-benzimidazol-1-yl)acetyl]amino]benzoate.

8.(currently amended) A compound selected from the group consisting of: N-(3-Fluoro-4-methoxy-phenyl)-2-(7-nitro-1H-benzimidazol-1-yl)-acetamide, N-[2-Fluoro-4-(trifluoromethyl)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide, N-(3-Chloro-4-iodophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide, N-(3-Chloro-4-methoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide, N-[3-(Difluoromethoxy)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide, N-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

- N-(3,5-Difluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethoxy)phenyl]acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]acetamide,
- N-(4-tert-Butylphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-[3-(1-Hydroxyethyl)phenyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethyl)phenyl]acetamide,
- N-(3-Chlorophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-Hexyl-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-(3,4-Difluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-(4-Cyanophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-(2-Bromobenzyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)benzyl]acetamide,
- N-(4-Methylpyridin-2-yl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-(3-Cyanophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-(3,5-Dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-(4-Methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-(3-Ethoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-(3,4-Dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(3,4,5-trimethoxyphenyl)acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethoxy)phenyl]acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-N-(3-phenoxyphenyl)acetamide,
- N-(4-Butylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-(2-Fluoro-4-iodophenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[2-(trifluoromethoxy)phenyl]acetamide,
- N-(4-Methoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(2-phenoxyphenyl)acetamide,
- N-(4-Bromo-2-fluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-[3-(Methylsulfonyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-[4-(Methylsulfonyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethyl)benzyl]acetamide,
- N-(4-tert-Butylbenzyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-(2,3-dihydro-1H-inden-5-yl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,

- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethoxy)benzyl]acetamide,
- N-(4-Isopropylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-(3,4-Dimethylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-1,3-Benzodioxol-5-yl-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-[3-Bromo-4-(trifluoromethoxy)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- N-(3-Fluoro-2-methoxyphenyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide,
- N-(3,5-dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)propanamide,
- N-(3-Ethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)propanamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]propanamide,
- N-(3,5-Dimethylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
- 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
- 2-(7-Bromo-1H-benzimidazol-1-yl)-N-(3,5-dimethoxyphenyl)acetamide,
- 2-(7-Bromo-1H-benzimidazol-1-yl)-N-(3-methoxyphenyl)acetamide,
- 2-(7-Bromo-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
- 2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
- 2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
- 2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(4-methylphenyl)acetamide,
- 2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(2,3-dihydro-1*H*-inden-5-yl)acetamide,
- 2-(7-Methyl-1H-benzimidazol-1-yl)-N-(4-methylphenyl)acetamide,
- N-(3,5-Dimethoxyphenyl)-2-(7-methyl-1H-benzimidazol-1-yl)acetamide,
- 2-(7-Methyl-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
- N-(2,3-Dihydro-1H-inden-5-yl)-2-(7-methyl-1H-benzimidazol-1-yl)acetamide,
- Methyl 1-{2-[(3,4-dimethylphenyl)amino]-2-oxoethyl}-1*H*-benzimidazole-7-carboxylate,
- Methyl 1-[2-(2,3-dihydro-1*H*-inden-5-ylamino)-2-oxoethyl]-1*H*-benzimidazole-7-carboxylate,
- Methyl 1-{2-[(4-tert-butylbenzyl)amino]-2-oxoethyl}-1H-benzimidazole-7-carboxylate,
- Methyl 1-(2-{[3-methoxy-5-(trifluoromethyl)phenyl]amino}-2-oxoethyl)-1*H*-benzimidazole-7-carboxylate,
- Methyl 1-{2-[(3,5-dimethoxyphenyl)amino]-2-oxoethyl}-1*H*-benzimidazole-7-carboxylate,
- N-(3,5-Dimethoxyphenyl)-2-{7-[(dimethylamino)sulfonyl]-1H-benzimidazol-1-yl}acetamide,
- 2-{7-[(Dimethylamino)sulfonyl]-1H-benzimidazol-1-yl}-N-[3-
- (trifluoromethyl)phenyl]acetamide,
- N-(3,5-Dimethoxyphenyl)-2-[7-(propylsulfonyl)-1H-benzimidazol-1-yl]acetamide,

- 2-[7-(Propylsulfonyl)-1H-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
- *N*-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-[7-(methylsulfonyl)-1*H*-benzimidazol-1-yl]acetamide,
- N-(3,5-Dimethoxyphenyl)-2-[7-(trifluoromethyl)-1H-benzimidazol-1-yl]acetamide,
- N-(3,4-Dimethylphenyl)-2-[7-(trifluoromethyl)-1H-benzimidazol-1-yl]acetamide,
- N-(4-tert-Butylbenzyl)-2-[7-(trifluoromethyl)-1H-benzimidazol-1-yl]acetamide,
- N-(2,3-Dihydro-1*H*-inden-5-yl)-2-[7-(trifluoromethyl)-1*H*-benzimidazol-1-yl]acetamide,
- 2-(7-Cyano-1*H*-benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
- 2-(7-Cyano-1*H*-benzimidazol-1-yl)-*N*-(3-methoxyphenyl)acetamide,
- 2-(7-Cyano-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
- 2-(7-Cyano-1*H*-benzimidazol-1-yl)-*N*-(2,3-dihydro-1*H*-inden-5-yl)acetamide,
- N-(2,3-Dihydro-1*H*-inden-5-yl)-2-(7-fluoro-1*H*-benzimidazol-1-yl)acetamide,
- N-(3,5-Dimethoxyphenyl)-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
- N-(4-tert-Butylbenzyl)-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide,
- 2-(7-Amino-1*H*-benzoimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
- 2-[7-(Acetylamino)-1H-benzoimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
- 2-{7-[(Methylsulfonyl)amino]-1H-benzoimidazol-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide,
- 2-[7-(Dimethylamino)-1H-benzoimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
- 2-[7-(Isopropylamino)-1H-benzoimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
- N-(3,5-Dimethoxyphenyl)-2-[7-(1H-tetrazol-5-yl)-1H-benzimidazol-1-yl] acetamide, and
- 2-(6,7-Difluoro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, or a pharmaceutically acceptable salt thereof, solvate or solvated salt thereof.
- 9.(previously amended) A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to claim 1, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.